# Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases

> **NCT05465863** · NA · COMPLETED · sponsor: **Istanbul University - Cerrahpasa** · enrollment: 101 (actual)

## Conditions studied

- Chronic Kidney Disease 5D
- Chronic Kidney Disease 5T

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)

## Key facts

- **NCT ID:** NCT05465863
- **Lead sponsor:** Istanbul University - Cerrahpasa
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465863, "Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05465863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*